Monthly Archives October 2019

Tampa General Hospital’s New Diagnostic Center Delivers World-Class Treatment to the Sun City Center Community

SUN CITY CENTER, Florida, October 18, 2019 / PRNewswire / – Tampa General Hospital has opened a new 10,000 square foot diagnostic center, located at 16521 US 301 in Wimauma, which includes an emergency care clinic, primary care practice, diagnostic imaging and laboratory.

A unique offering is a full-time pivot nurse who will provide guidance to community members by assisting them with future appointments or by answering specific clinical questions. The Navigator can help with things such as: explaining medication instructions; find health care providers for specific needs; inquire about transportation options for medical appointments; and generally help with basic questions people may have about where and how to get medical attention. The browser will help patients find the right provider, even outside the TGH network.

The service is free, no insurance is required. Navigation services are available from 8 a.m. to 5 p.m. Monday to Friday. Walk-in people are welcome or community members can call (813) 660-6763.

It is believed to be the first service of its kind in the Tampa Bay Region.

“Healthcare can be confusing, and our goal is to eliminate confusion and help patients navigate their healthcare journey,” said Adam smith, TGH Senior Vice President for Outpatient Services.

The Tampa General Hospital Diagnostic Center includes:

  • TGH Urgent Care Powered by Fast Track Clinic, open seven days a week, from 8 a.m. to 8 p.m. Clinic health care providers can manage common illnesses and injuries without an appointment. Patients can make appointments online, or as a date.
  • Primary care physicians from the Tampa General Medical Group will be available to see patients. Doctors are Dr. Jeffrey Lister and Dr. Sheena spielberg, both of whom are certified in internal medicine. Patients can also be seen by Gloria Ossa, a registered nurse in advanced practice. Make an appointment at or by calling (813) 844-4700. A list of insurance policies accepted by providers of Tampa General Medical Group can be found here.
  • Tower Radiology, providing services such as X-rays, mammography, DEXA scans and ultrasound. Appointments can be scheduled via an online request or by calling (813) 874-3177.
  • Laboratory services are also provided. Appointments can be made by calling (813) 844-4700. Walk-ins are also accepted.

The goal of the TGH Diagnostic Center is the convenience of community members. The center also offers a layout that conforms to a preferred mode of transport in the Downtown of the sun community – a golf cart charging station.

“We are creating services that meet the needs of the community in their neighborhood, where it is most convenient,” Smith said.

Tampa General Hospital, a 1,007-bed nonprofit academic medical center, provides world-class care as the region’s only center for Level 1 trauma and comprehensive burn care. It is one of the busiest adult solid organ transplant centers in the country and is the main teaching hospital of USF Health Morsani College of Medicine. With five medical helicopters, Tampa General Hospital transports critically injured and ill patients from 23 surrounding counties to receive the advanced care they need. Tampa General is home to a nationally accredited comprehensive stroke center and its 32-bed neuroscience intensive care unit is the largest on the west coast of Florida. It also houses an 82-bed level IV neonatal intensive care unit and a state-certified spinal cord and brain rehabilitation center. The Tampa General Hospital footprint includes 14 primary care offices of Tampa General Medical Group, TGH Family Care Center Kennedy, TGH Brandon Healthplex, TGH Virtual Care, 15 outpatient radiology centers, and a TGH Urgent Care located in Brandon. As one of the largest hospitals in Florida, Tampa General Hospital is the first in the state to open a command center in partnership with GE Healthcare. For more information visit

Media contact: Curtis Krueger
Senior Public Relations Specialist
(o) (813) 844-7322
(c) (727) 580-1813
[email protected]

Tampa General Hospital

Related links

Source link

Neurolign advances with acquisition of Eye Diagnostic Technology Company

Neurolign, Neurologic and Pharmaceutical Diagnostics Company Advances Diagnostics with Acquisition of Neuro Kinetics Inc., a Leader in Non-invasive Neurofunctional Eye Tracking Diagnostic Tests

TORONTO, October 10, 2019 / CNW / – Neurolign Technologies Inc. (“Neurolign”) today announced the acquisition of Neuro Kinetics Inc. from Pittsburgh, Pennsylvania, a global leader in clinical eye monitoring and non-invasive neurofunctional diagnostic tests, offering cutting-edge neurofunctional assessments.

Neurolign is a privately held pharmaceutical and diagnostic company focused on providing superior diagnostic solutions and new therapies for the diagnosis and treatment of neurological disorders to physicians and their patients. The founder of Neurolign is Eugene Melnyk, the creator of several healthcare companies, including Biovail Corporation (acquired by Bausch Health), and the current owner of Ottawa Senators Hockey Club. Through this transaction, Neurolign will acquire the assets and operations of Neuro Kinetics, including customer relationships, all products, technologies, related intellectual property, property, plant and equipment, and assume certain responsibilities.

“Acquisition of Neuro Kinetics accelerates Neurolign’s mission to research, develop and provide access to world-class diagnostics and targeted pharmaceutical therapies to improve the lives of patients with neurological disorders, starting initially with concussion.” , said Eugene Melnyk, Chairman and CEO of Neurolign. “After observing concussed athletes in sport and its impact on these athletes and their families, there is a need to advance the abilities of clinicians to diagnose and determine when athletes can safely return to sport. We will address this issue. transforming not only the diagnosis and treatment of concussions, but also for a wide range of neurological disorders affecting the global community. ”

“Traumatic brain injury, TBI, is a global public health epidemic and a growing concern for military health,” says David Okonkwo, MD, Ph, D ,, professor of neurosurgery at the University of Pittsburgh and Director, Center for Clinical Trials in Neurotrauma. “There is an urgent need for new innovative technologies that provide objective diagnostic data for TBI. This investment in Neuro Kinetics can accelerate the development and commercialization of this new technology and take the lead in diagnostics in multiple dimensions of brain health. “

Neuro Kinetics is the leader in providing eye tracking platforms offering the most accurate and data rich eye tracking diagnostic solution on the global market today. With over 90 variables and 14 FDA approved tests, Neuro Kinetics solutions include its critical assets, I-PAS ™ and I-Portal ™. These foundational platforms help clinicians identify more than 200 diseases and medical conditions early, accurately and cost-effectively. The non-invasive science of I-Portal enables Neuro Kinetics to expand its presence in the vestibular market into new areas and applications in head trauma, concussion, ophthalmology and neurology.

“We look forward to the next phase of growth and development for the company and are very excited to merge with Neurolign,” said Howison Schroeder, President and CEO of Neuro Kinetics. Schroeder added, “The opportunities created by this transaction provide us with the support we need to advance our planned developments for the assessment of additional neurological diseases. “

About Neurolign Technologies Inc.
Neurolign Technologies is dedicated to creating quantum change in the diagnosis and treatment of neurodegenerative diseases. Through the unique combination of high precision medical devices along with specialized formulations and drug delivery technologies, Neurolign creates a revolutionary approach to the assessment and treatment of brain injury and disease. Whether you are a patient or a healthcare professional, our world-class diagnostics and new therapies can support the pursuit of optimal brain health. Our portfolio and services offer a holistic and evidence-based ability to provide more accurate and timely diagnostic and treatment options. Further information on Neurolign is available at

About Neuro Kinétique Inc.
Neuro Kinetics, Inc. is the leader in clinical eye tracking and non-invasive neurofunctional diagnosis and monitoring, providing technology that identifies abnormal eye responses linked to more than 200 diseases and medical conditions. With over 30 years of experience and over 150 installations, Neuro Kinetics’ FDA-approved I-Portal® devices are sold to physiotherapists, audiologists, ENT specialists, neuro-chiropractors, neuro-ophthalmologists and neurologists around the world. The company’s FDA-approved diagnostic platforms include I-PAS ™ (I-Portal® Portable Assessment System), I-Portal® NOTC (Neuro-Otologic Test Center), I-Portal® VNG, (Video Nystagmography ) and I-Portal ® VOG (Video Oculography), as well as related accessories, software, training and support services. You can find information about Neuro Kinetics at

Caution regarding forward-looking information
Certain statements contained in this document constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and / or “forward-looking information” under the Securities Act (Ontario). These statements include, without limitation, express or implied statements regarding our expectations regarding our plans, objectives and milestones, the status of developments or expenses relating to our business, plans for financing our current activities and statements. regarding our partnership activities, regulatory submissions in matters of health, strategy, future operations, future financial position, future sales, revenues and profitability, projected costs and market penetration and risks or uncertainties. In some cases, you can identify forward-looking statements by words such as “appear”, “unlikely”, “target”, “could”, “,” anticipate “,” believe “,” believe “,” predict “, “confident”, “prospect”, “potential”, “continue”, “intend to”, “foresee”, “could”, “would”, “planned”, “goals”, “set at”, ” research ”or the negative of those terms or other comparable terminology. We have made a number of assumptions in the preparation of our forward-looking statements. You should not place undue reliance on our forward-looking statements, which are subject to scrutiny. multitude of known and unknown risks and uncertainties that could cause actual results, circumstances or future events to differ materially from those stated or implied by forward-looking statements. future events and are based s on what we believe to be reasonable assumptions as of the date of this document and we disclaim any intention and have no obligation or liability, except as required by law, to update or revise any forward-looking statement, whether this either as a result of new information, future events or otherwise.

Derek clark, COO, Neurolign Technologies Inc.
Phone: 1-800-503-3804
E-mail: [email protected]

Related images

Corporate image of Neurolign
Corporate image of Neurolign

SOURCE Neurolign Technologies Inc

Related links

Source link

ProciseDx and Lumiphore Announce Diagnostic Technology Partnership

SAN DIEGO and BERKELEY, Calif., October 8, 2019 / PRNewswire / – ProciseDx and Lumiphore have announced that they have signed an agreement to incorporate Lumiphore’s new metallic luminescent protractor technology into ProciseDx ™ point-of-care diagnostic testing.

Under the agreement, ProciseDx owns the exclusive worldwide rights to use Lumiphore’s new technology in its diagnostic tests. The first offers will concern inflammatory and autoimmune diseases such as celiac and metabolic syndromes.

“Lumiphore can bring the benefits of homogeneity based on lanthanides mix and read tests, known as time-resolved fluorescence resonance energy transfer (TR-FRET) assays, to diagnostic markets, from central laboratories to point-of-care applications. Detection sensitivity and ease of use as well as material cost reductions in reagent use, labor and reading platforms are all benefits of Lumiphore’s new reporting technology ” , said Steve Blose, Lumiphore Commercial Director.

“Using Lumiphore’s technology enables ProciseDx to provide fast, quantitative and easy point-of-care testing. We are excited to bring these tests to market in 2020. ”said Dr. Larry Mimms, CEO of ProciseDx.

About ProciseDx

ProciseDx is a diagnostic company engaged in the development and commercialization of a broad portfolio of point-of-care diagnostic tests for use in physician’s offices, retail clinics and emergency care. ProciseDx currently has 24 employees, 10,000 square feet of office, laboratory and manufacturing space and is ISO13485 certified. ProciseDx is headquartered at San diego, california and is a 100% subsidiary of Nestlé Health Science.

For more information about Procise Dx, please visit us at

About Lumiphore, Inc.

Situated at Berkeley, California, Lumiphore Inc, a privately held company, is a biotechnology leader in the development of proprietary luminescent metal lanthanide reporters as well as metal radionuclide payload delivery technology for use in directed diagnostic and radiopharmaceutical applications on site. , respectively. Lumiphore’s technology is commercialized through market-specific alliances with business partners. Lumiphore holds exclusive licenses for the fundamental science developed in University of California, Berkeley in the professor’s lab Kenneth N. Raymond, a world expert in lanthanide chemistry.

For more information on Lumiphore, log on to

Media contacts
Lumiphore, Inc.
Stephane Blose
[email protected]
+1 415-318-4457

ProciseDx, LLC.
Peter Westlake
[email protected]
+ 1 619-821-0660

SOURCE ProciseDx; Lumiphore

Related links

Source link